본문 바로가기
KERD
논문KCI 등재후보

2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension

김근호|박성하|채성철|김현창|이장훈|편욱범|Jinho Shin|Hae-Young Lee|Sang-Hyun Ihm|Kwang-il Kim|Ju Han Kim
대한고혈압학회 (The Korean Society of Hypertension)|2019.12|Clinical Hypertension|제25권 제4호|pp. 51-74|DOI https://doi.org/10.1186/s40885-019-0124-x

2

조회

0

다운로드

72

인용

0

참고문헌

키워드

GuidelinesHypertensionLifestyleMeasurementBlood pressureCardiovascular riskAntihypertensive treatment

초록

The standardized techniques of blood pressure (BP) measurement in the clinic are emphasized and it is recommended to replace the mercury sphygmomanometer by a non-mercury sphygmomanometer. Out-of-office BP measurement using home BP monitoring (HBPM) or ambulatory BP monitoring (ABPM) and even automated office BP (AOBP) are recommended to correctly measure the patient’s genuine BP. Hypertension (HTN) treatment should be individualized based on cardiovascular (CV) risk and the level of BP. Based on the recent clinical study data proving benefits of intensive BP lowering in the high risk patients, the revised guideline recommends the more intensive BP lowering in high risk patients including the elderly population. Lifestyle modifications, mostly low salt diet and weight reduction, are strongly recommended in the population with elevated BP and prehypertension and all hypertensive patients. In patients with BP higher than 160/100 mmHg or more than 20/10 mmHg above the target BP, two drugs can be prescribed in combination to maximize the antihypertensive effect and to achieve rapid BP control. Especially, single pill combination drugs have multiple benefits, including maximizing reduction of BP, minimizing adverse effects, increasing adherence, and preventing cardiovascular disease (CVD) and target organ damage.

Abstract

The standardized techniques of blood pressure (BP) measurement in the clinic are emphasized and it is recommended to replace the mercury sphygmomanometer by a non-mercury sphygmomanometer. Out-of-office BP measurement using home BP monitoring (HBPM) or ambulatory BP monitoring (ABPM) and even automated office BP (AOBP) are recommended to correctly measure the patient’s genuine BP. Hypertension (HTN) treatment should be individualized based on cardiovascular (CV) risk and the level of BP. Based on the recent clinical study data proving benefits of intensive BP lowering in the high risk patients, the revised guideline recommends the more intensive BP lowering in high risk patients including the elderly population. Lifestyle modifications, mostly low salt diet and weight reduction, are strongly recommended in the population with elevated BP and prehypertension and all hypertensive patients. In patients with BP higher than 160/100 mmHg or more than 20/10 mmHg above the target BP, two drugs can be prescribed in combination to maximize the antihypertensive effect and to achieve rapid BP control. Especially, single pill combination drugs have multiple benefits, including maximizing reduction of BP, minimizing adverse effects, increasing adherence, and preventing cardiovascular disease (CVD) and target organ damage.

참고문헌 (167)

  1. Williams B, "2018 ESC", ESH guidelines for the management of arterial hypertension, 2018, pp.39(33), 3021~3104
  2. Chobanian AV, "Seventh report of the joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure", Hypertension, 42(6), pp.1206~1252 (2003)
  3. Verberk WJ, "Self-measurement of blood pressure at home reduces the need for antihypertensive drugs : a randomized, controlled trial", Hypertension, 50(6), pp.1019~1025 (2007)
  4. Kario K, "Guidance on home blood pressure monitoring : a statement of the HOPE Asia network", J Clin Hypertens, 20(3), pp.456~461 (2018)
  5. Cappuccio FP, "Blood pressure control by home monitoring : meta-analysis of randomised trials", BMJ, 329(7458), pp.145~ (2004)
  6. McManus RJ, "Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease : the TASMIN-SR randomized clinical trial", JAMA, 312(8), pp.799~808 (2014)
  7. The Korean Society of Hypertension, "Blood pressure monitoring guidelines (Korean)", ~ (2007)
  8. Staessen JA, "Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic hypertension in Europe trial Investigators", JAMA, 282(6), pp.539~546 (1999)
  9. Ohkubo T, "Prognosis of"masked"hypertension and"white-coat"hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study", J Am Coll Cardiol, 46(3), pp.508~515 (2005)
  10. Pickering TG, "Ambulatory blood-pressure monitoring", N Engl J Med, 354(22), pp.2368~2374 (2006)
  11. Pickering TG, "Recommendations for blood pressure measurement in humans and experimental animals : part 1 : blood pressure measurement in humans : a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on high blood pressure research", Circulation, 111(5), pp.697~716 (2005)
  12. 김배근, "A Reverse Dipping Pattern Predicts Cardiovascular Mortality In a Clinical Cohort", Journal of Korean Medical Science, 28(10), pp.1468~1473 (2013), 대한의학회
  13. Hamada T, "The clinical significance of abnormal diurnal blood pressure variation in healthy late middle-aged and older adults", Blood Press, 17(3), pp.134~140 (2008)
  14. Profant J, "Race and diurnal blood pressure patterns. A review and meta-analysis", Hypertension, 33(5), pp.1099~1104 (1999)
  15. Armstrong D, "Automated office blood pressure-being alone and not location is what matters most", Blood Pressure Monitoring, 20(4), pp.204~208 (2015)
  16. Myers MG, "Thresholds for diagnosing hypertension based on automated office blood pressure measurements and cardiovascular risk", Hypertension, 66(3), pp.489~495 (2015)
  17. Kjeldsen SE, "The un-observed automated office blood pressure measurement technique used in the SPRINT study points to a standard target office systolic blood pressure <140 mmHg", Curr Hypertens Rep, 19(1), pp.3~ (2017)
  18. Filipovsky J, "Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients", Blood Press, 25(4), pp.228~234 (2016)
  19. McEniery CM, "Central blood pressure : current evidence and clinical importance", Eur Heart J, 35(26), pp.1719~1725 (2014)
  20. Roman MJ, "Central pressure more strongly relates to vascular disease and outcome than does brachial pressure : the strong heart study", Hypertension, 50(1), pp.197~203 (2007)
  21. Lim S, "In creasing treands of metabolic syndrome in Korea – based on Korean National Health and nutrition examination surveys", J Kor Diabetes Assoc, 29, pp.8~ (2005)
  22. Mancia G, "2013ESH", ESC guidelines for the management of arterial hypertension : the task force for the management of arterial hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC), 2013, pp.31(7), 1281~1357
  23. The Korean Society of Lipid and Atherosclerosis, "Korean guidelines for the management of dyslipidemia(Korean)", ~ (2009)
  24. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension, "Guidelines Subcommittee", J Hypertens, 17(2), pp.151~183 (1999)
  25. European Society of Hypertension-European Society of Cardiology Guidelines, Committee, "2003 European Society of Hypertension-European Society of cardiology guidelines for the management of arterial hypertension", J Hypertens, 21(6), pp.1011~1053 (2003)
  26. Jung KJ, "The ACC", AHA 2013pooled cohort equations compared to a Korean risk prediction model for atherosclerotic cardiovascular disease, 2015, pp.242(1), 367~375
  27. Asia Pacific Cohort Studies C, "The impact of cardiovascular risk factors on the age-related excess risk of coronary heart disease", Int J Epidemiol, 35(4), pp.1025~1033 (2006)
  28. Lloyd-Jones DM, "Lifetime risk of developing coronary heart disease", Lancet, 353(9147), pp.89~92 (1999)
  29. Moran A, "The future impact of population growth and aging on coronary heart disease in China : projections from the coronary heart disease policy model-China", BMC Public Health, 8, pp.394~ (2008)
  30. Lewington S, "Agespecific relevance of usual blood pressure to vascular mortality : a metaanalysis of individual data for one million adults in 61 prospective studies", Lancet, 360(9349), pp.1903~1913 (2002)
  31. Lonn EM, "Bloodpressure lowering in intermediate-risk persons without cardiovascular disease", N Engl J Med, 374(21), pp.2009~2020 (2016)
  32. Zanchetti A, "When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal", J Hypertens, 27(5), pp.923~934 (2009)
  33. Whelton PK, "Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE collaborative research group", JAMA, 279(11), pp.839~846 (1998)
  34. Whelton PK, "Primary prevention of hypertension : clinical and public health advisory from the National High Blood Pressure Education Program", JAMA : the journal of the American Medical Association, 288(15), pp.1882~1888 (2002)
  35. Whelton PK, "Efficacy of nonpharmacologic interventions in adults with high-normal blood pressure: results from phase 1 of the trials of hypertension prevention. Trials of hypertension prevention collaborative research group", Am J Clin Nutr, 65(2 Suppl), pp.652S~660 (1997)
  36. Appel LJ, "Effects of comprehensive lifestyle modification on blood pressure control : main results of the PREMIER clinical trial", JAMA, 289(16), pp.2083~2093 (2003)
  37. Group SR, "A randomized trial of intensive versus standard blood-pressure control", N Engl J Med, 373(22), pp.2103~2116 (2015)
  38. Wang YC, "Prevalence of masked hypertension among US adults with nonelevated clinic blood pressure", Am J Epidemiol, 185(3), pp.194~202 (2017)
  39. Luders S, "The PHARAO study : prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure : a prospective, randomized, controlled prevention trial of the German hypertension league", J Hypertens, 26(7), pp.1487~1496 (2008)
  40. Julius S, "Feasibility of treating prehypertension with an angiotensin-receptor blocker", N Engl J Med, 354(16), pp.1685~1697 (2006)
  41. Dagenais GR, "Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose : results of the diabetes REduction assessment with ramipril and rosiglitazone medication(DREAM)trial", Diabetes Care, 31(5), pp.1007~1014 (2008)
  42. McMurray JJ, "Effect of valsartan on the incidence of diabetes and cardiovascular events", N Engl J Med, 362(16), pp.1477~1490 (2010)
  43. Schrier RW, "Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes", Kidney Int, 61(3), pp.1086~1097 (2002)
  44. Arima H, "Lower target blood pressures are safe and effective for the prevention of recurrent stroke : the PROGRESS trial", J Hypertens, 24(6), pp.1201~1208 (2006)
  45. Zanchetti A, "How much should blood pressure be lowered? The problem of the Jshaped curve", J Hypertens Suppl, 7(6), pp.S338~48 (1989)
  46. Thomopoulos C, "Effects at different baseline and achieved blood pressure levels--overview and meta-analyses of randomized trials", J Hypertens, 32(12), pp.2296~2304 (2014)
  47. Sundstrom J, "Effects of blood pressure reduction in mild hypertension", Ann Intern Med, 163(1), pp.67~68 (2015)
  48. Collins R, "Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease", Br Med Bull, 50(2), pp.272~298 (1994)
  49. Law MR, "Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies", Bmj, 338, pp.b1665~ (2009)
  50. Zanchetti A, "Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?", J Hypertens, 27(8), pp.1509~1520 (2009)
  51. Medical Research Council Working Party, "MRC trial of treatment of mild hypertension: principal results", Br Med J, 291(6488), pp.97~104 (1985)
  52. "The Australian therapeutic trial in mild hypertension", Lancet, 1(8181), pp.1261~1267 (1980)
  53. Sundstrom J, "Effects of blood pressure reduction in mild hypertension : a systematic review and meta-analysis", Ann Intern Med, 162(3), pp.184~191 (2015)
  54. Williamson JD, "Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >", =75 years : a randomized clinical trial, 2016, pp.315(24), 2673~2682
  55. Beckett NS, "Treatment of hypertension in patients 80 years of age or older", N Engl J Med, 358(18), pp.1887~1898 (2008)
  56. Xie X, "Effects of intensive blood pressure lowering on cardiovascular and renal outcomes : updated systematic review and meta-analysis", Lancet, 387(10017), pp.435~443 (2016)
  57. Thomopoulos C, "Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials", J Hypertens, 34(4), pp.613~622 (2016)
  58. Liu L, "The Felodipine event reduction(FEVER)study : a randomized long-term placebo-controlled trial in Chinese hypertensive patients", J Hypertens, 23(12), pp.2157~2172 (2005)
  59. Zhang Y, "Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial", Eur Heart J, 32(12), pp.1500~1508 (2011)
  60. Weiss J, "Benefits and harms of intensive blood pressure treatment in adults aged 60years or older : a systematic review and meta-analysis", Ann Intern Med, 166(6), pp.419~429 (2017)
  61. Bavishi C, "Outcomes of intensive blood pressure lowering in older hypertensive patients", J Am Coll Cardiol, 69(5), pp.486~493 (2017)
  62. JATOS Study Group, "Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients(JATOS)", Hypertens Res, 31(12), pp.2115~2127 (2008)
  63. Ogihara T, "Target blood pressure for treatment of isolated systolic hypertension in the elderly : valsartan in elderly isolated systolic hypertension study", Hypertension, 56(2), pp.196~202 (2010)
  64. Cushman WC, "Effects of intensive blood-pressure control in type 2 diabetes mellitus", N Engl J Med, 362(17), pp.1575~1585 (2010)
  65. Patel A, "Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2diabetes mellitus(the ADVANCE trial) : a randomised controlled trial", Lancet, 370(9590), pp.829~840 (2007)
  66. Emdin CA, "Blood pressure lowering in type 2 diabetes : a systematic review and meta-analysis", JAMA, 313(6), pp.603~615 (2015)
  67. Brunstrom M, "Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus : systematic review and meta-analyses", Bmj, 352, pp.i717~ (2016)
  68. Hansson L, "Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : principal results of the hypertension optimal treatment(HOT)randomised trial", HOT Study Group Lancet, 351(9118), pp.1755~1762 (1998)
  69. UK Prospective Diabetes Study Group, "Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38", Bmj, 317(7160), pp.703~713 (1998)
  70. Buckley LF, "Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP", Diabetes Care, 40(12), pp.1733~1738 (2017)
  71. Reboldi G, "Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes : a meta-analysis in 73, 913 patients", J Hypertens, 29(7), pp.1253~1269 (2011)
  72. PATS Collaborating Group, "Poststroke antihypertensive treatment study. A preliminary result", Chin Med J(Engl), 108, pp.8~ (1995)
  73. Progress Collaborative Group, "Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack", Lancet, 358(9287), pp.1033~1041 (2001)
  74. Rashid P, "Blood pressure reduction and secondary prevention of stroke and other vascular events : a systematic review", Stroke, 34(11), pp.2741~2748 (2003)
  75. Ovbiagele B, "Level of systolic blood pressure within the normal range and risk of recurrent stroke", JAMA, 306(19), pp.2137~2144 (2011)
  76. Yusuf S, "Telmisartan to prevent recurrent stroke and cardiovascular events", N Engl J Med, 359(12), pp.1225~1237 (2008)
  77. Fox KM, "Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)", Lancet, 362(9386), pp.782~788 (2003)
  78. Poole-Wilson PA, "Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment(ACTION trial) : randomised controlled trial", Lancet, 364(9437), pp.849~857 (2004)
  79. Braunwald E, "Angiotensin-converting-enzyme inhibition in stable coronary artery disease", N Engl J Med, 351(20), pp.2058~2068 (2004)
  80. Upadhyay A, "Systematic review : blood pressure target in chronic kidney disease and proteinuria as an effect modifier", Ann Intern Med, 154(8), pp.541~548 (2011)
  81. Arguedas JA, "Treatment blood pressure targets for hypertension", The Cochrane database of systematic reviews, 3, pp.CD004349~ (2009)
  82. Appel LJ, "Intensive blood-pressure control in hypertensive chronic kidney disease", N Engl J Med, 363(10), pp.918~929 (2010)
  83. Klahr S, "The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease", N Engl J Med, 330(13), pp.877~884 (1994)
  84. Wright JT Jr, "Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease : results from the AASK trial", JAMA : the journal of the American Medical Association, 288(19), pp.2421~2431 (2002)
  85. Ruggenenti P, "Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease(REIN-2) : multicentre, randomised controlled trial", Lancet, 365(9463), pp.939~946 (2005)
  86. Sarnak MJ, "The effect of a lower target blood pressure on the progression of kidney disease : long-term follow-up of the modification of diet in renal disease study", Ann Intern Med, 142(5), pp.342~351 (2005)
  87. Kovesdy CP, "Hypertension in chronic kidney disease after the Systolic Blood Pressure Intervention Trial: targets, treatment and current uncertainties", Nephrol. Dial. Transplant, 32(suppl_2), pp.219~223 (2017)
  88. Rabkin SW, "The impact of left ventricular mass on diastolic blood pressure targets for patients with coronary artery disease", Am J Hypertens, 29(9), pp.1085~1093 (2016)
  89. Bangalore S, "What is the optimal blood pressure in patients after acute coronary syndromes? : relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin evaluation and infection therapythrombolysis in myocardial infarction(PROVE IT-TIMI)22 trial", Circulation, 122(21), pp.2142~2151 (2010)
  90. Bangalore S, "J-curve revisited : an analysis of blood pressure and cardiovascular events in the treating to new targets(TNT)trial", Eur Heart J, 31(23), pp.2897~2908 (2010)
  91. Messerli FH, "Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?", Ann Intern Med, 144(12), pp.884~893 (2006)
  92. Messerli FH, "J curve in hypertension and coronary artery disease", Am J Cardiol, 95(1), pp.160~ (2005)
  93. Myers MG, "Unfounded concerns about the use of automated office blood pressure measurement in SPRINT", J Am Soc Hypertens, 10(12), pp.903~905 (2016)
  94. Mozaffarian D, "Global sodium consumption and death from cardiovascular causes", N Engl J Med, 371(7), pp.624~634 (2014)
  95. Cook NR, "Long term effects of dietary sodium reduction on cardiovascular disease outcomes : observational follow-up of the trials of hypertension prevention(TOHP)", Bmj, 334(7599), pp.885~888 (2007)
  96. Sacks FM, "Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet", N Engl J Med, 344(1), pp.3~10 (2001)
  97. Neter JE, "Influence of weight reduction on blood pressure : a meta-analysis of randomized controlled trials", Hypertension, 42(5), pp.878~884 (2003)
  98. Elmer PJ, "Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control : 18-month results of a randomized trial", Ann Intern Med, 144(7), pp.485~495 (2006)
  99. He FJ, "Nutrition in cardiovascular disease : salt in hypertension and heart failure", Eur Heart J, 32(24), pp.3073~3080 (2011)
  100. Bibbins-Domingo K, "Projected effect of dietary salt reductions on future cardiovascular disease", N Engl J Med, 362(7), pp.590~599 (2010)
  101. He FJ, "Salt reduction lowers cardiovascular risk : metaanalysis of outcome trials", Lancet, 378(9789), pp.380~382 (2011)
  102. 2010 Korean Natrional Health Statistics. 2010 Korean National Health and Nutrition Examination Survey 2010, , ~
  103. Korea National Health and Nutrition Examination Survey(Korean), "Korea Centers for Disease Control and Prevention", ~ (2016)
  104. Rhee MY, "Sodium intake of a city population in Korea estimated by 24-h urine collection method", Eur J Clin Nutr, 67(8), pp.875~880 (2013)
  105. Park S, "Association of central hemodynamics with estimated 24-h urinary sodium in patients with hypertension", J Hypertens, 29(8), pp.1502~1507 (2011)
  106. He FJ, "How far should salt intake be reduced?", Hypertension, 42(6), pp.1093~1099 (2003)
  107. Graudal NA, "Effects of low-sodium diet vs. highsodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane review)", Am J Hypertens, 25(1), pp.1~15 (2012)
  108. Taylor RS, "Reduced dietary salt for the prevention of cardiovascular disease : a meta-analysis of randomized controlled trials(Cochrane review)", Am J Hypertens, 24(8), pp.843~853 (2011)
  109. O'Donnell MJ, "Salt intake and cardiovascular disease: why are the data inconsistent?", Eur Heart J, 34(14), pp.1034~1040 (2013)
  110. Flegal KM, "Association of all-cause mortality with overweight and obesity using standard body mass index categories : a systematic review and meta-analysis", JAMA, 309(1), pp.71~82 (2013)
  111. Xin X, "Effects of alcohol reduction on blood pressure : a meta-analysis of randomized controlled trials", Hypertension, 38(5), pp.1112~1117 (2001)
  112. Leung AA, "Hypertension Canada's 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension", Can J Cardiol, 32(5), pp.569~588 (2016)
  113. Jae SY, "Temporal changes in cardiorespiratory fitness and the incidence of hypertension in initially normotensive subjects", Am J Hum Biol, 24(6), pp.763~767 (2012)
  114. Cornelissen VA, "Impact of resistance training on blood pressure and other cardiovascular risk factors : a meta-analysis of randomized, controlled trials", Hypertension, 58(5), pp.950~958 (2011)
  115. Doll R, "Mortality in relation to smoking : 40 years' observations on male British doctors", Bmj, 309(6959), pp.901~911 (1994)
  116. Manson JE, "The primary prevention of myocardial infarction", N Engl J Med, 326(21), pp.1406~1416 (1992)
  117. Rosenberg L, "The risk of myocardial infarction after quitting smoking in men under 55 years of age", N Engl J Med, 313(24), pp.1511~1514 (1985)
  118. Mann SJ, "Elevation of ambulatory systolic blood pressure in hypertensive smokers. A case-control study", JAMA, 265(17), pp.2226~2228 (1991)
  119. Ndanuko RN, "Dietary patterns and blood pressure in adults : a systematic review and metaanalysis of randomized controlled trials", Adv Nutr, 7(1), pp.76~89 (2016)
  120. Estruch R, "Primary prevention of cardiovascular disease with a Mediterranean diet", N Engl J Med, 368(14), pp.1279~1290 (2013)
  121. Appel LJ, "A clinical trial of the effects of dietary patterns on blood pressure", N Engl J Med, 336(16), pp.1117~1124 (1997)
  122. Obarzanek E, "Effects on blood lipids of a blood pressure-lowering diet : the dietary approaches to stop hypertension(DASH)trial", Am J Clin Nutr, 74(1), pp.80~89 (2001)
  123. Sacks FM, "A dietary approach to prevent hypertension: a review of the dietary approaches to stop hypertension (DASH) study", Clin Cardiol, 22(7 Suppl), pp.6~10 (1999)
  124. Svetkey LP, "Effects of dietary patterns on blood pressure : subgroup analysis of the dietary approaches to stop hypertension(DASH)randomized clinical trial", Arch Intern Med, 159(3), pp.285~293 (1999)
  125. 신지예, "Associations between dietary patterns and hypertension among Korean adults: the Korean National Health and Nutrition Examination Survey (2008-2010)", Nutrition Research and Practice, 7(3), pp.224~232 (2013), 한국영양학회[DOI]
  126. Kostis JB, "Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension", JAMA, 278(3), pp.212~216 (1997)
  127. "Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension", JAMA, 265(24), pp.3255~3264 (1991)
  128. Staessen JA, "Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension", Lancet, 350(9080), pp.757~764 (1997)
  129. Julius S, "Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine : the VALUE randomised trial", Lancet, 363(9426), pp.2022~2031 (2004)
  130. Martell N, "Trough to peak ratio of once-daily lisinopril and twice-daily captopril in patients with essential hypertension", J Hum Hypertens, 12(1), pp.69~72 (1998)
  131. Lipicky RJ, "Trough : peak ratio : the rationale behind the United States Food and Drug Administration recommendations", J Hypertens Supplement, 12(8), pp.S17~18 (1994)
  132. Tung YC, "Medication compliance and clinical outcomes of fixed-dose combinations vs free combinations of an angiotensin II receptor blocker and a calcium channel blocker in hypertension treatment", J Clin Hypertens, 19(10), pp.983~989 (2017)
  133. Roush GC, "Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events : systematic review and network meta-analyses", Hypertension, 59(6), pp.1110~1117 (2012)
  134. Roush GC, "Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone : antihypertensive and metabolic effects", Hypertension, 65(5), pp.1041~1046 (2015)
  135. Agarwal R, "Thiazide diuretics in advanced chronic kidney disease", J Am Soc Hypertens, 6(5), pp.299~308 (2012)
  136. Williams B, "Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension(PATHWAY-2) : a randomised, double-blind, crossover trial", Lancet, 386(10008), pp.2059~2068 (2015)
  137. Krieger EM, "Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension : the ReHOT randomized study(resistant hypertension optimal treatment)", Hypertension, 71(4), pp.681~690 (2018)
  138. Park K, "Physiologic evaluation of myocardial bridging : a new analysis for an old disease", Can J Cardiol, 27(5), pp.596~600 (2011)
  139. Elliott WJ, "Incident diabetes in clinical trials of antihypertensive drugs : a network meta-analysis", Lancet, 369(9557), pp.201~207 (2007)
  140. Keller KB, "Prinzmetal's angina", Am J Crit Care, 13(4), pp.350~354 (2004)
  141. Campbell NR, "Canadian hypertension education program : the science supporting new 2011 CHEP recommendations with an emphasis on health advocacy and knowledge translation", Can J Cardiol, 27(4), pp.407~414 (2011)
  142. Bakris GL, "Metabolic effects of carvedilol vs metoprolol in patients with type 2diabetes mellitus and hypertension : a randomized controlled trial", JAMA, 292(18), pp.2227~2236 (2004)
  143. Celik T, "Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients", J Hypertens, 24(3), pp.591~596 (2006)
  144. Mancia G, "Reappraisal of European guidelines on hypertension management : a European Society of Hypertension Task Force document", J Hypertens, 27(11), pp.2121~2158 (2009)
  145. Brown NJ, "Angiotensin-converting enzyme inhibitors", Circulation, 97(14), pp.1411~1420 (1998)
  146. Palmer BF, "Managing hyperkalemia caused by inhibitors of the reninangiotensin-aldosterone system", N Engl J Med, 351(6), pp.585~592 (2004)
  147. Bicket DP, "Using ACE inhibitors appropriately", Am Fam Physician, 66(3), pp.461~468 (2002)
  148. Wald DS, "Combination therapy versus monotherapy in reducing blood pressure : meta-analysis on 11, 000participants from 42 trials", Am J Med, 122(3), pp.290~300 (2009)
  149. Gupta P, "Risk factors for nonadherence to antihypertensive treatment", Hypertension, 69(6), pp.1113~1120 (2017)
  150. Jamerson K, "Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients", N Engl J Med, 359(23), pp.2417~2428 (2008)
  151. Mann JF, "Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk(the ONTARGET study) : a multicentre, randomised, doubleblind, controlled trial", Lancet, 372(9638), pp.547~553 (2008)
  152. Parving HH, "Cardiorenal end points in a trial of aliskiren for type 2 diabetes", N Engl J Med, 367(23), pp.2204~2213 (2012)
  153. Yusuf S, "Telmisartan, ramipril, or both in patients at high risk for vascular events", N Engl J Med, 358(15), pp.1547~1559 (2008)
  154. Denolle T, "Management of resistant hypertension : expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology", J Hum Hypertens, 30(11), pp.657~663 (2016)
  155. Persell SD, "Prevalence of resistant hypertension in the United States, 2003-2008", Hypertension, 57(6), pp.1076~1080 (2011)
  156. Zannad F, "Aldosterone antagonist therapy in resistant hypertension", J Hypertens, 25(4), pp.747~750 (2007)
  157. Chapman N, "Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian cardiac outcomes trial", Circulation, 118(1), pp.42~48 (2008)
  158. Bobrie G, "Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension : a prospective, randomized, open blinded endpoint study", J Hypertens, 30(8), pp.1656~1664 (2012)
  159. Gaddam KK, "Characterization of resistant hypertension : association between resistant hypertension, aldosterone, and persistent intravascular volume expansion", Arch Intern Med, 168(11), pp.1159~1164 (2008)
  160. Bhatt DL, "A controlled trial of renal denervation for resistant hypertension", N Engl J Med, 370(15), pp.1393~1401 (2014)
  161. Rosa J, "Role of adding spironolactone and renal denervation in true resistant hypertension : one-year outcomes of randomized PRAGUE-15 study", Hypertension, 67(2), pp.397~403 (2016)
  162. Baigent C, "Aspirin in the primary and secondary prevention of vascular disease : collaborative meta-analysis of individual participant data from randomised trials", Lancet, 373(9678), pp.1849~1860 (2009)
  163. Jardine MJ, "Aspirin is beneficial in hypertensive patients with chronic kidney disease : a post-hoc subgroup analysis of a randomized controlled trial", J Am Coll Cardiol, 56(12), pp.956~965 (2010)
  164. Ridker PM, "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein", N Engl J Med, 359(21), pp.2195~2207 (2008)
  165. Baigent C, "Cholesterol treatment Trialists, collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000participants in 26 randomised trials", Lancet, 376(9753), pp.1670~1681 (2010)
  166. Amarenco P, "High-dose atorvastatin after stroke or transient ischemic attack", N Engl J Med, 355(6), pp.549~559 (2006)
  167. Association KD, "Treatment guideline for diabetes", ~ (2015)

관련 논문AI추천

2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II—treatments of hypertension김광일, 김권호, 김영권, 김주한, 박정배, 변욱범, 신진호, 양동현, 채성철대한고혈압학회 · Clinical Hypertension2015 · 제21권 제2호The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension김광일, 김영권, 김주한, 김학령, 김현창, 박성하, 박종무, 신진호, 안신영, 이은미, 이장훈, 이해영, 조은주대한고혈압학회 · Clinical Hypertension2023 · 제29권 2018 Korean Society of Hypertension guidelines for the management of hypertension: part I-epidemiology of hypertension김근호, 김현창, 박성하, 신진호, 이장훈, 채성철, 편욱범, Hae-Young Lee, Jong-Moo Park, Ju Han Kim, Kwang-Il Kim, Sang-Hyun Ihm대한고혈압학회 · Clinical Hypertension2019 · 제25권 제4호고혈압의 진단 및 치료: 대한고혈압학회 진료지침을 기반으로안계택, 정진옥, 진선아대한신경과학회 · 대한신경과학회지2019 · 제37권 제2호2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations김현창, 박성하, 이장훈, 채성철, 편욱범, Gheun-Ho Kim, Hae-Young Lee, inho Shin, Jang Hoon Lee, Jong-Moo Park, Ju Han Kim, Kwang-Il Kim대한고혈압학회 · Clinical Hypertension2019 · 제25권 제4호2013 Korean Society of Hypertension guidelines for the management of hypertension. Part I—epidemiology and diagnosis of hypertension김광일, 김권호, 김영권, 김주한, 박정배, 변욱범, 신진호, 양동현, 채성철, 대한고혈압학회대한고혈압학회 · Clinical Hypertension2015 · 제21권 제1호

이 간행물의 다른 논문 (15건)

Could Management of Blood Pressure Prevent Dementia in the elderly?Masaki Mogipp. 8-12Prevalence and associated factors of preeclampsia among pregnant women attending anti-natal care at Mettu Karl referal hospital, Ethiopia: cross-sectional studyAlemayehu Sayih Belay, Tofik Wudadpp. 8-15Differences in prevalence of hypertension subtypes according to the 2018 Korean Society of Hypertension and 2017 American College of Cardiology/American Heart Association guidelines: The Korean National Health and Nutrition Examination Survey, 2007–2017 (KNHANES IV-VII)조소미, 이호규, 김현창pp. 13-24Red cell distribution width and preeclampsia: a systematic review and meta-analysisIshag Adam, Elfatih M. Malik, Theonest K. Mutabingwapp. 16-23Familial aggregation and heritability of hypertension in Han population in Shanghai China: a case-control studyXian-hong Yin, An-le Li, Yi-ying Zhang, Qian Peng, Xiang Fangpp. 24-30
원문 보기